Endocrinology Unit and Centro di Ricerca Biomedica Applicata, Department of Clinical Medicine, S. Orsola-Malpighi Hospital, Alma Mater University of Bologna, Bologna 40138, Italy.
Trends Mol Med. 2011 Sep;17(9):518-26. doi: 10.1016/j.molmed.2011.05.002. Epub 2011 Aug 2.
Dysregulation of the endocannabinoid system (ECS) is a universal and, perhaps, causative feature of obesity. Central nervous system (CNS) circuits that regulate food intake were initially believed to be the targets for dysregulation. However, it is increasingly evident that endocannabinoids affect food intake, energy expenditure and substrate metabolism by acting on peripheral sites. Cannabinoid type 1 receptor (CB1r) antagonists can effectively treat obesity and associated metabolic alterations but, unfortunately, cause and exacerbate mood disorders. Drugs restricted to act on peripheral CB1rs might be safer and more effective, retaining the anti-obesity effects but lacking the adverse neurodepressive reactions. This review summarizes the emerging roles of the ECS in energy balance and discusses future pharmacological approaches for developing peripherally restricted CB1r antagonists.
内源性大麻素系统 (ECS) 的失调是肥胖的普遍特征,甚至可能是其病因。最初,人们认为调节食物摄入的中枢神经系统 (CNS) 回路是失调的靶点。然而,越来越明显的是,内源性大麻素通过作用于外周部位来影响食物摄入、能量消耗和底物代谢。大麻素 1 型受体 (CB1r) 拮抗剂可有效治疗肥胖症和相关代谢紊乱,但不幸的是,会引起和加重情绪障碍。仅作用于外周 CB1r 的药物可能更安全、更有效,保留抗肥胖作用,但没有不良的神经抑制反应。本综述总结了 ECS 在能量平衡中的新作用,并讨论了开发外周受限 CB1r 拮抗剂的未来药理学方法。